Search results

Sounds like the metabolic trap is back to being an untested hypothesis. :(

Does the paper specify where the KYN/TRP was sampled from? Phair has stated that the KYN and TRP of significance is intracellular, which isn't an easy measurement to make.

I would have expected more spin from Reuter's Kelland if SMC had pushed this. Her coverage seems more in line with her simply having been assigned the story since she's covered related stories in the past.

It seems to be typical for this sort of study. Usually they will include the minimum number of subjects required to still produce a statistically significant result if the hypothesis being tested is indeed true. And if it checks out, then they will follow it up with higher powered, more...

Why is it so often said that ME/CFS is the last major disease we know almost nothing about? I get that there is still lots left to discover. We haven't even isolated the primary disease mechanism, or if we have we dont recognize it as such yet. But aren't there already nearly ten thousand ME/CFS...

I know very little about the molecular biology of such things, but I have wondered if the poor RBC deformability could be the product of Naviaux's Cell Danger Response. IIRC, part of the CDR involves a stiffening of the cell membrane. If this is the case, and it could be behind the RBC low...

From Linda Tannenbaum So it seems it is published in Blood Journal..

Here are the details of the current work being done on RBC deformability as posted by OMF on November 13th of this year. https://www.omf.ngo/2018/11/13/triple-tuesday-research-update/

I'm curious what sort of scenario might make it 'bad' to publish a finding of this sort in a top journal?

Happy to see Ron Davis publishing

I'm unfamiliar with how such things typically work but, could a open letter be drafted with the support of all the major ME/CFS organizations as well as professionals stating the concerns about the NICE review process? Is that the best way to put these concerns on to the public record? Does...

Klimas also mentioned recently that an ME/CFS patient had helped raise half the money needed for the ME/CFS Men's subgroup pilot trial, which she said should be enough to at least get started on it, hopefully by the end of this year. Exciting stuff!

I feel like ME/CFS clinicians would be the best people to help recruit for the NIH study since they are the ones who have direct contact with the most patients, and probably a lot of patients who are being newly diagnosed. I wonder if that's being done.

What I dont understand is how Cochrane seemingly didn't anticipate this much push-back from the BPS crowd when they started down this road of withdrawal. And then of course, upon receiving push-back, how they didn't think "whoa, this is the wrong way to do science", and double down on their...

https://www.syndromea.org/2018/10/29/autism-and-chronic-fatigue-syndrome/?fbclid=IwAR1s1EgFoxNtBKJ5a_1s7zotCIakO_I5b7cfPlRRYSHXAOMRzUaBSZdDtKI

This is beyond the pale. So it's YOUR "intense fatigue" that's most important here?? What a thing to say to a patient population of millions whose lives have been left in rubble by a lack of energy.

And Larun's camp wouldn't have leaked this to the press in an effort to apply public pressure on Cochrane unless all other efforts to resolve this had failed. This is the ultimate hail mary. It's their highest card they can play at this juncture, and they know it's a low card.

Ugh. Medscape ran the Reuters story https://www.medscape.com/viewarticle/903621?src=wnl_edit_tpal&uac=265282FG&impID=1773388&faf=1&fbclid=IwAR0QbNUHVhHy5h-N7xv7lW4KR1QH-yilJsDC0w4bvlZhXxVDKCbV6njY4MQ

"“in response to concerns raised by members of the CFS community” they are considering moving responsibility for research reviews on CFS/ME away from their mental health department into another section — possibly the “long-term conditions” section." This review may only be concerned with GET...

I dont recall Phair mentioning the TDO enzyme. Was it just implied?